TD Asset Management’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-187,788
| Closed | -$6.01M | – | 1435 |
|
|
2024
Q3 | $6.01M | Buy |
187,788
+13,600
| +8% | +$468K | 0.01% | 755 |
|
|
2024
Q2 | $4.71M | Buy |
174,188
+33,400
| +24% | +$659K | ﹤0.01% | 776 |
|
|
2024
Q1 | $3.04M | Buy |
140,788
+46,766
| +50% | +$1.02M | ﹤0.01% | 898 |
|
|
2023
Q4 | $567K | Sell |
94,022
-27,400
| -23% | -$137K | ﹤0.01% | 1283 |
|
|
2023
Q3 | $675K | Buy |
121,422
+72,811
| +150% | +$469K | ﹤0.01% | 1219 |
|
|
2023
Q2 | $357K | Buy |
48,611
+11,000
| +29% | +$83.3K | ﹤0.01% | 1311 |
|
|
2023
Q1 | $148K | Hold |
37,611
| – | – | ﹤0.01% | 1392 |
|
|
2022
Q4 | $119K | Hold |
37,611
| – | – | ﹤0.01% | 1411 |
|
|
2022
Q3 | $135K | Hold |
37,611
| – | – | ﹤0.01% | 1420 |
|
|
2022
Q2 | $116K | Sell |
37,611
-13
| -0% | -$60 | ﹤0.01% | 1408 |
|
|
2022
Q1 | $195K | Sell |
37,624
-13,226
| -26% | -$62.7K | ﹤0.01% | 1433 |
|
|
2021
Q4 | $246K | Sell |
50,850
-6,425
| -11% | -$43.7K | ﹤0.01% | 1441 |
|
|
2021
Q3 | $510K | Buy |
57,275
+40,282
| +237% | +$372K | ﹤0.01% | 1385 |
|
|
2021
Q2 | $153K | Hold |
16,993
| – | – | ﹤0.01% | 1494 |
|
|
2021
Q1 | $277K | Buy |
+16,993
| New | +$278K | ﹤0.01% | 1453 |
|
TD Asset Management's LBPH Position: Q4 2024 in Review
TD Asset Management sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 187,788 shares — an estimated $6.01M sold.
TD Asset Management first reported a position in LBPH in Q1 2021 and held it in 15 quarters. The position peaked at $6.01M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.
- TD Asset Management reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- TD Asset Management sold 187,788 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $6.01M.
- TD Asset Management first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 15 quarters.
- TD Asset Management's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $6.01M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on TD Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.